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Summary
Growth hormone (GH) is widely prescribed for children with
short stature across a range of growth disorders. Recombinant
human (rh) insulin-like growth factor-1 (rhIGF-1) therapy is
approved for severe primary IGF-I deficiency – a state of severe
GH resistance. Evidence is increasing for an unacceptably high
rate of poor or unsatisfactory response to growth-promoting ther-
apy (i.e. not leading to significant catch up growth) in terms of
change in height standard deviation score (SDS) and height veloc-
ity (HV) in many approved indications. Consequently, there is a
need to define poor response and to prevent or correct it by opti-
mizing treatment regimens within accepted guidelines. Recogni-
tion of a poor response is an indication for action by the treating
physician, either to modify the therapy or to review the primary
diagnosis leading either to discontinuation or change of therapy.
This review discusses the optimal investigation of the child who is
a candidate for GH or IGF-1 therapy so that a diagnosis-based
choice of therapy and dosage can be made. The relevant parame-
ters in the evaluation of growth response are described together
with the definitions of poor response. Prevention of poor response
is addressed by discussion of strategy for first-year management
with GH and IGF-1. Adherence to therapy is reviewed as is the
recommended action following the identification of the poorly
responding patient. The awareness, recognition and management
of poor response to growth-promoting therapy will lead to better
patient care, greater cost-effectiveness and increased opportunities
for clinical benefit.
(Received 16 January 2012; returned for revision 13 February
2012; finally revised 17 April 2012; accepted 17 April 2012)
Introduction
The management of short stature comprises many challenges,
not least the options of appropriate hormonal therapies and
their administration in regimens that are most beneficial. GH
therapy is licensed by the European Medicines Agency (EMA)
for treatment of GH deficiency (GHD), Turner syndrome (TS),
short stature related to birth size small for gestational age
(SGA), Prader–Willi syndrome, SHOX deficiency, and chronic
renal insufficiency. In the USA, the Food and Drugs Administra-
tion (FDA) has in addition approved GH therapy for idiopathic
short stature (ISS) and Noonan syndrome. Recombinant human
(rh)IGF-1 therapy is licensed by the EMA and FDA for treat-
ment of severe primary IGF-I deficiency, characterized by spe-
cific criteria.1
As experience with different treatment regimens accumulates,
it is clear from reports of GH treatment that individual first-year
height responses vary considerably2–4 even with individualized
treatment regimens.5 Poor short-term response is also translated
into an unsatisfactory gain in adult height.6
This review addresses the identification and management of
poor or unsatisfactory growth responses in children with licensed
indications for growth-promoting therapy. We discuss the inves-
tigation of short stature aimed at establishing a diagnosis, the
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parameters of response, factors predicting response, decisions
relating to start of therapy, the problem of adherence and finally
the management of the poorly responding patient.
The continuum of growth disorders
Growth disorders exist across a continuum ranging from
extreme GH sensitivity to extreme GH resistance.1,7 An extensive
review of the different genetic growth disorders in this contin-
uum has recently been published.8 An inherent component of
the continuum is the variation in responsiveness to GH therapy.
It is now well recognized that children with severe GHD are
highly responsive to GH replacement4,9 and patients with less
severe or questionable GHD often respond less well. In recent
reports of GH responses, there were no differences in response
between subjects with less severe GHD and those with ‘normal’
GH secretion labelled as having ISS.4,10 A strict distinction can-
not be drawn between GHD and ISS and as the continuum of
responsiveness to GH varies across and within diagnostic groups,
the relevance of relating a sufficient response to a specific diag-
nosis can be questioned.
In disorders of GH resistance, the effect of GH therapy further
decreases and rhIGF-1 treatment is indicated.11,12 Criteria for
lack of response to rhIGF-1 similarly need to be defined.
Clinical assessment and investigations aimed at
identification of a primary diagnosis
Clinical assessment and investigation are important because the
choice of therapy and dosage should be related to the primary
diagnosis. The predicted response depends on a number of vari-
ables identified at initial assessment.
History and physical examination
The history and physical examination are essential13,14 and
attention should be paid to premature and/or SGA (low birth-
weight or birth-length) birth. The presence of chronic disease
should be considered and dysmorphic features should be docu-
mented. Parental heights are relevant and known to be related
to the response to GH.
Hormonal status
The identification of genetic defects in the GH–IGF-axis8 has
underlined the importance of endocrine assessment including
determination of serum IGF-I and GH secretion. Recently, a
consensus on GH and IGF-I determinations was published.15
Measurement of IGFBP-3, acid-labile subunit (ALS) and GH
binding protein (GHBP) may be considered, as may an IGF-I
generation test and eventually molecular analysis for candidate
gene defects.8 Severe classic GHD should be diagnosed early in
patients with neonatal symptoms of hypoglycaemia and pro-
longed jaundice, a characteristic growth pattern and possible
additional pituitary hormone deficiencies. GHD in these chil-
dren and in those with less severe idiopathic GHD (IGHD) are
conventionally confirmed by a low IGF-I concentration and GH
provocative testing with a GH cut-off set at 7 or 10 lg/l.
However, this cut-off leads to a separation between IGHD
and ISS that lacks physiological evidence as indicated by similar
responsiveness to GH treatment.4 Furthermore, as many as 50%
of GH-treated children with short stature, born SGA have low
stimulated GH concentrations.4 Poor reproducibility and a high
incidence of false subnormal responses to different pharmacolog-
ical stimuli are further limitations of GH stimulation tests.13,15
The difficulties in discriminating between IGHD and ISS or SGA
were clarified by the study of Kristro¨m et al.5 and in the report
of Loche et al.16 who showed that 85% of IGHD patients with
two stimulated peak GH values <10 lg/l and normal pituitary
magnetic resonance imaging (MRI) had values of GH > 10 lg/l
when re-tested 1–6 months later.
Serum IGF-I levels are not only largely GH dependent, but
are also influenced by age, pubertal development, malnutrition,
chronic inflammation or hepatic diseases. A subnormal (<2 SD)
IGF-I concentration indicates that GH testing should be per-
formed but cannot take its place. Evaluation of spontaneous
nocturnal GH secretion is used in a small number of centres and
may have higher predictive value for the response to GH treat-
ment, although this remains to be confirmed.17
If GH secretion is normal, IGF-I deficiency, provided chronic
disease has been excluded, may be ‘primary’ (i.e. primary IGF-I
deficiency) indicating GH resistance, with possible sites being
the GH receptor, GH post-receptor signalling including defects
in STAT5b or the IGF1 gene.8 A defect in circulating IGF-I
transport as a result of a mutation in the IGFALS gene may be a
more frequent cause of primary IGF-I deficiency, although
growth retardation is milder.18,19 To investigate GH resistance,
the IGF-I generation test may be helpful but the results are sel-
dom clear-cut except in extreme GH resistance, and the test
should not be mandatory.8,20
Radiological assessment
Magnetic resonance imaging of the hypothalamic–pituitary
region must be performed when GHD is diagnosed, to exclude
an organic cause. Skeletal survey is indicated for body dispro-
portion and an x-ray of the left hand and wrist for bone age,
although not diagnostic, may be relevant to management.
Genetic assessment
In certain children, the family history and clinical features may
suggest a single gene defect. Key features are the presence of one
or more of the following: a positive family history, parental con-
sanguinity, severe growth failure, facial dysmorphism caused by
IGF-I deficiency as a result of extreme GHD or GH resistance,
immune deficiency, intrauterine growth retardation, deafness
and microcephaly.21 Single gene defects in the GH–IGF-I axis
may involve hypothalamic–pituitary development, GH secretion,
GH binding to its receptor, intracellular GH signalling and IGF-I
synthesis and action. The available genetic techniques currently
in use in growth assessment are shown in Fig. 1.
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Relevant parameters in the evaluation of GH
response
A number of factors are key determinants of the pattern of
response to GH treatment.6,9,17 Assessment of responses to
IGF-I therapy will be discussed later. In this section, we con-
sider the prepubertal response to GH treatment as the short-
term height response in a pubertal subject may be difficult to
interpret. GH dose and growth response during the first year of
GH therapy are strong predictors of final height outcome.9,17,22
–25 In prepubertal GH-treated children with IGHD, a first-year
height increase of 0·5 standard deviation score (SDS) corre-
sponds to an average final height gain of approximately
1·0 SDS.26 A number of possible growth response parameters
are considered.
Growth during the first year of GH therapy: parameters
of response
Increase in height SDS and height velocity (HV). Increase in
height SDS is perhaps the most relevant parameter for the
patient and parents, as deviation in growth relative to peers and
the demonstration of how the patient’s height will change with
therapy is clinically and psychologically important. This also
impacts on adherence. The increase in height SDS can easily be
calculated. HV is also easy to discuss with the patient and
parents. However, the actual increase in cm/year (i.e. annualized
HV) that results in a gain in height compared with peers is
dependent on age. Both HV and increase in height SDS are
endpoints in growth prediction models and first-year HV is the
standard endpoint in clinical trials.
HV SDS and increase in HV. Expressing the HV SDS of a child
on GH with reference to healthy children is hampered by the
lack of reference data. Available data are based on longitudinal
studies in small numbers of healthy children or on cross-
sectional data. HV SDS in the first and subsequent years of GH
treatment may have a non-linear relationship with age.3
Determinations of increase in HV, comparing annualized HV
during the first year on GH with that of the pretreatment year,
are often restricted by absence or lack of reliable data. HV in a
healthy child changes over time and pretreatment data should
be derived from a full year.27 Given the caveats of these two
growth response measures, they will not be discussed further in
this article.
Age-dependency of responses
Increases in height SDS and HV during the first year on GH
treatment in different diagnoses (Table 1) are strongly age
dependent.3,4,10 This age dependency is largely explained by the
physiology of normal linear growth. Firstly, the equivalence of
1·0 height SDS is approximately 3, 5 and 6 cm at ages of 2, 7
and 11 years respectively.28 Although mean heights at given ages
differ in different populations, the width of 1·0 height SDS is
relatively stable across populations, at least prepubertally
(unpublished observations). Secondly, HV values in healthy chil-
dren also change with age, with the young child growing much
faster. Normal mean HVs are approximately 9, 6 and 5 cm/year
at ages of 2, 7 and 11 years respectively. Therefore, a higher pro-
portion of children with a given diagnosis starting GH at a
younger age will gain 1·0 height SDS and have higher HV values
during the first year of treatment compared with children start-
ing GH at an older age.4 Several clinical trials and post-market-
ing registries report data on mean (±SD) or median
(percentiles) first-year height responses or gain in final height in
GH-treated children (Table 1). These studies consistently report
better responses when treatment is started at an early age – the
number of years of prepubertal GH treatment strongly predict-
ing final height.22–25,29
References from NCGS and KIGS databases
Recently, age-, sex- and diagnosis-specific references have been
derived from large numbers of GH-treated prepubertal children
registered in the National Cooperative Growth Study (NCGS)
History
• Growth history
• Birth weight/length
• Family history: consanguinity, affected siblings
• Developmental milestones
Documentation of phenotype
• Expanded auxology
• Dysmorphic features
GH–IGF-axis related genetic defects
• Sequencing and mutational analysis of 
 candidate genes (Examples: PROP1, POU1F1, LHX3, 
 GHR, STAT5b, IGF1, IGFALS, IGF1R, PTPN-11)
• Methylation analysis (Silver-Russell syndrome)
• Homozygosity mapping, whole exome 
 sequencing (unexplained short stature in 
 consanguineous families)
Assessment of GH–IGF-I axis
Likely GH–IGF-I 
defect
Unlikely GH–IGF-I 
defect
GH–IGF-axis non-related genetic defects
• Array comparative genomic hybridization (SOX3, 
 unrecognized syndromes)
• FISH (Prader-Willi syndrome, GHD + mental retardation, 
 Williams syndrome, SHOX)
• Duplication/deletion analysis (X-linked chondrodysplasia, 
 hypophosphataemic rickets)
• Cytogenetic analysis (Turner syndrome, Bloom syndrome)
• Homozygosity mapping, Whole exome sequencing
Fig. 1 Scheme for genetic investigation of short stature with available genetic techniques and examples of disorders for which they are appropriate.21,66
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(n = 7000) and Pfizer International Growth Database (KIGS)
(n = 8500).3,10 Reference data of increase in first-year height
SDS or HV during GH therapy allow assessment of height
response in patients with IGHD, organic GHD (OGHD), ISS
and TS.3 In the NCGS cohort,3 the patients were not divided
according to the severity of GHD, as they were in the KIGS
cohort.10 In the latter cohort, reference data exist for IGHD,
separated into severe (peak GH < 5 lg/l) or less severe (peak
GH 5–10 lg/l) deficiency, TS or SGA.10 These references reflect
the patient selection and the prescription and management rou-
tines of the past. The usefulness of such references, therefore,
may be limited if these routines change as a result of current
focus and discussion of poor response and its management. The
mean first-year HV curve of subjects with less severe IGHD trea-
ted with GH reported by Ranke et al. was superimposable on
the mean HV 1·0 SD curve for IGHD reported by Bakker
et al. (Fig. 2a). This may be explained by the 40–50% larger GH
dose used in the USA and that a greater proportion of children
with severe GHD with higher responsiveness were included in
the Bakker series.
Response related to diagnosis
Arguably, a major limitation of the age-related and sex- and
diagnosis-specific references is that none includes all GH indica-
tions. However, the variation in response within each diagnostic
group largely overrides the difference in mean HV curves among
the different diagnoses (Table 1). For example, the KIGS data10
show that the mean HV curve of subjects with severe IGHD
only differs from those of less severe IGHD and SGA by approx-
imately 1·5 cm/year over the entire age range (Fig. 2b). This dif-
ference is within the variability in response for each diagnosis
(the width of one SD is ~2·5 cm/year for severe GHD and
~1·5 cm/year for less severe GHD and SGA). It is therefore
debatable whether there is a need for more than one reference
to which any given patient independent of diagnosis could be
compared. The response to GH in severe GHD could be used as
such a reference. This approach to define poor response would
be consistent with the concept of a continuum of responsiveness
in the GH–IGF-axis. Importantly, it also acknowledges that in a
higher proportion of patients with less severe GHD, SGA, ISS
and TS, sensitivity to GH is decreased and the response to GH
is poor.
Definitions of poor response
If diagnosis-, sex- and age-specific references are not used,
another strategy to define the minimal acceptable growth
response is required. Several diagnosis-, age- and sex-non-spe-
cific definitions of poor first-year GH treatment response have
been proposed. These include an increase in height SDS <0·3 or
<0·5, an increase in HV <3 cm/year and an increase in HV SDS
<+1 SD compared with healthy children.10,14,30–32
The first study to define the proportion of patients who did
not exceed these cut-offs was reported recently.4 Responses to
GH were analysed in 456 short, prepubertal Nordic children,
and the numbers of children with a first-year increase in height
SDS < 0·5 ranged from almost 30% in IGHD (including those
born SGA) and OGHD, a similar percentage in ISS, almost 50%
in SGA and almost 60% in TS and skeletal dysplasia (Fig. 3).
After excluding those with severe IGHD (peak GH < 3 lg/l),
IGHD patients did not differ in their mean HV response vs
those with ISS or SGA. Furthermore, responsiveness to GH in
SGA patients with IGHD (peak GH < 10 lg/l) was not different
from that in patients with less severe IGHD.4
Consensus on the definition of a poor or inadequate first-
year GH response, however, is lacking,33 as indicated at recent
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Fig. 2 (a) HV during the first year on GH therapy in prepubertal
children with less severe IGHD (stimulated peak GH 5–10 lg/l)
registered in the KIGS database, represented by the 50th, 25th and 10th
percentiles (grey lines), derived from the report by Ranke et al.10
Superimposed are data on HV in patients with IGHD (peak GH not
defined) registered in the NCGS database, represented by the mean,
mean HV 1 SD and mean HV 2 SD (black lines) derived from the
report by Bakker et al.3 (b) HV data in less severe IGHD (grey) are
superimposed with data from children with severe IGHD (stimulated
peak GH < 5 lg/l; black) and SGA (light grey), adapted from Ranke
et al.10 IGHD, idiopathic growth hormone deficiency; HV, height
velocity; SGA, small for gestational age.
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consensus workshops on ISS14 and SGA.34 Bakker et al.3 sug-
gested that patients with a first-year HV <mean HV 1·0 SD
for that sex and diagnosis should be labelled as poor respond-
ers.3 Similarly, Ranke argued that using the same cut-off, a
poor response equals a gain in height SDS of <0·4 in a
patient with severe GHD and an increase in height SDS of
<0·3 in patients with less-severe GHD, girls with TS or SGA
subjects.10
However, at ages 3–8 years, an increase in height SDS of <0·3
is within the normal variation of height measures observed over
a 1-year period.35 A sufficient height response to GH treatment
should lead to catch-up toward the target height36 and must ide-
ally be distinguishable from the normal variation in height in
healthy children, and therefore the cut-offs suggested by Bakker
et al. and Ranke et al. may not identify all children with a true
poor response to therapy.
Definition of clinical benefit
An acceptable treatment response should equate to or exceed a
level at which a measurable clinical benefit for the patient has
been shown. In conditions where the main objective is to
improve short-term height and normalize adult stature, the
impact on quality of life should be considered. New data on
quality of life in children receiving GH therapy have recently
been published.37 In severe GHD, normalization of body com-
position and metabolism are also a goal of treatment.
Biomarkers of GH response
Short-term markers of growth response such as IGF-I, IGFBP-3
and bone matrix components may improve predictions of first-
year response to GH treatment.5,22 Basal and short-term changes
in IGF-I and IGFBP-3 are related to the first-year height SDS
and HV changes in subjects with GHD.4,38 Markers of bone
turnover such as alkaline phosphatase, bone alkaline phospha-
tase, osteocalcin and procollagen type 1 C-terminal propeptide,
and urinary markers of bone resorption increased significantly
during the first year of GH therapy in GH-deficient patients and
formed part of a prediction model of GH response.39 However,
these early markers of response to GH treatment are not used
routinely.40
Prediction of response to GH therapy
Growth prediction models
Over 10 years ago, the relative inflexibility of GH treatment reg-
imens and the simplicity of the modalities used to derive them
led to the introduction of mathematical models aimed at pre-
dicting growth responses in individual patients.9,17 Such models
attempt to account for the definable variability of responsiveness
so that clinicians can adapt GH doses to individual patients.6
Prediction models for the first-year HV as well as the total
height gain were published for patients with GHD,9,17 TS41 or
SGA42 and for patients with varying degrees of GH secretion or
ISS.17,22,23
Based on multiple regression analyses, these models have
identified a number of factors that correlate with growth. For
example chronological age, birthweight SDS, height SDS, height
SDS minus target height SDS, GH peak during provocative tests
and dose of GH are key variables associated with the first-year
HV.9,17 Biochemical variables such as baseline IGF-I17 and lep-
tin22 have added to the prediction of response. Prediction mod-
els derived from the large KIGS database explain approximately
60% of the variability of response to GH therapy in patients
with GHD and 40% in subjects with ISS.6 We believe that pre-
diction models should be used where possible to calculate the
optimal starting GH dose and to help in dose adjustment where
indicated in different diagnoses.
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Fig. 3 Proportion of poor responders after 1 year of standard GH therapy in 456 short prepubertal children according to different definitions in each
diagnostic group as reported by Bang et al.4 HV < mean 1 SD of the first year on GH response according to Bakker et al.3 Bakker data are available
only for IGHD, ISS and Turner syndrome. HV, height velocity; IGHD, idiopathic growth hormone deficiency; OGHD, organic growth hormone
syndrome; SGA, small for gestational age; ISS, idiopathic short stature. Reproduced with permission from S. Karger AS, Basel. © 2011.
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Pharmaco-genomic and pharmaco-proteomic studies
The addition of pharmaco-genomic analyses to the above vari-
ables may increase the accuracy of prediction models. Results
following the addition of genomic data to prediction model cal-
culations and evidence of their enhancement of model perfor-
mance are keenly awaited. For example, the presence of the
exon 3 deletion polymorphism in the GH receptor may enhance
the response to GH therapy in some subjects,43 notably those
with severe GHD44 as may the presence of the 202 A polymor-
phism in the IGFBP-3 promotor gene.45 Patterns of changes in
gene expression in peripheral blood mononuclear cells have been
reported during GH therapy in GHD subjects, potentially lead-
ing to the ability to further predict GH responsiveness.46 Such
pharmaco-genetic investigations have great potential.47
In addition, an increasing number of proteomic approaches
can be expected such as that used by Hellgren et al.48 identifying
new potential GH responsive proteins such as transthyretin and
apolipoprotein A-II. So far, pharmaco-genomic and pharmaco-
proteomic markers have not been formally validated. However,
it appears that they may add only minor improvements to exist-
ing prediction models. Ongoing genetic studies such as the EPI-
GROW study (http://clinicaltrials.gov/ct2/show/NCT00710307)
by Ipsen or the PREDICT study (http://clinicaltrials.gov/ct2/
show/NCT00699855?term=predict+GH&rank=2) by Merck Ser-
ono may contribute new data on genomic markers of GH
response.
Management of the first year on GH therapy
Discussion of decision to treat and expected response
Before the start of GH treatment, the parents and child should
be fully informed about the underlying condition, the probable
pathophysiology of growth retardation, the rationale for GH
therapy and the evidence-based expected growth response. This
should be based on a prediction model calculation and should
reflect the large variability in response among individuals inher-
ent in the continuum in GH sensitivity. Likely duration of ther-
apy and the level of response at which discontinuation of
treatment will be decided must also be discussed. The decision
to start and stop treatment should be made in consultation with
the patient and parents. Interestingly, data in the KIGS database
on why GH treatment is being stopped do not include ‘poor
response’ as an option.49 A recent consensus statement on the
use of GH in ISS emphasized the importance of discouraging
the expectation that taller stature will improve quality of life.14
Dose of GH
The starting dose of GH depends on the diagnosis of the condi-
tion and is usually calculated according to weight or body sur-
face area. The recommended GH dose for each approved
indication may differ between countries and reflects the respon-
siveness to GH in the condition being treated. However, the rec-
ommended dose does not routinely consider the variation in
responsiveness within each diagnosis spanning the continuum of
growth disorders. In cases where high GH sensitivity is expected
including subjects with extreme GHD or obesity such as cranio-
pharyngioma patients, a lower starting dose is recommended.
Although differences in dosing during the first year of GH ther-
apy may exist among countries and centres,50 there is evidence
for adherence to the recommended doses within each indica-
tion.4 If assessment after 1 year of treatment (or after 6 months
if there is no increase in height SDS) shows that growth
response is inadequate, the dose of GH may be increased. In
some indications such as SGA34 and ISS,14 the recommended
maximum dose of GH may be used from start of treatment or
the dose may be increased as necessary. Comparison of GH dos-
ing approaches, involving discontinuous high-dose or continu-
ous lower-dose regimens, for example in SGA subjects51
concluded that a broad spectrum of GH regimens is effective.
In some situations, such as ISS, concern has been raised that
higher GH doses of up to approximately 70 lg/kg per day
advance bone age and pubertal progress,52 but this has not been
confirmed.53 There are no definitive data concerning the long-
term safety of doses higher than 50 lg/kg per day in children
with ISS. A GH dose of 70 lg/kg per day was approved in the
USA for treatment of GHD in puberty, but this regimen is
only used by one-third of centres.54 In December 2010, the
EMA issued guidance (http://www.ema.europa.eu/ema/index.jsp?
curl=pages/news_and_events/news/2010/12/news_detail_001167.
jsp&murl=menus/news_and_events/news_and_events.jsp&mid=
WC0b01ac058004d5c1) not to exceed a GH dose of 50 lg/kg
per day based on preliminary data from a French post-
marketing registry study, now published55 in addition to data
from Belgium, the Netherlands and Sweden.56 However, follow-
ing a review by the EMA’s Committee for Medicinal Products
for Human Use (CHMP) of available data on the safety of
somatropin (GH)-containing medicines, including data from
clinical trials, registries and observational studies, as well as
reports of side effects from post-marketing surveillance, it was
recently concluded that the benefit–risk balance of somatropin-
containing medicines remains positive when used in the licensed
indications at the approved doses (http://www.ema.europa.eu/
docs/en_GB/document_library/Referrals_document/somatropin_
107/WC500119354.pdf). It was recommended that the
maximum recommended daily dose should not be exceeded
Monitoring during GH therapy
During the first year of GH therapy, children should be seen at
3–6 monthly intervals for assessment of growth, puberty, mood
and body composition and to support compliance with therapy.
These visits may be used to judge response to GH, but growth
response cannot be reliably assessed at an interval shorter than
1 year27,57 GH dose adjustments during the first year of treat-
ment may not have been as common in the past and may be less
frequent in some countries4 than in others.54
IGF-I is a short-term biomarker of efficacy as well as a marker
for adherence to therapy. The significance of abnormally ele-
vated IGF-I levels in children on GH therapy remains unknown.
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However, it is recommended to consider GH dose reduction if
IGF-I is repeatedly above the upper limit of the normal range or
+2·5 SDS.14 Deciding the starting GH dose based on the Swedish
prediction model resulted in GH doses from 17 to 100 lg/kg
per day, but did not decrease the occurrence of serum IGF-I lev-
els above the normal range.5 However, this approach did result
in a smaller variability in height responses during the first
2 years of GH therapy compared with conventional dosing. In
SGA, the recommended maximum dose of 0·067 mg/kg per day
increased IGF-I far above the normal range,58 although the
height response was not similarly increased.
Monitoring of parameters of glucose metabolism may be per-
formed, although there is little evidence for its clinical relevance
except in children with chronic inflammation receiving gluco-
corticoid therapy59 or in conditions such as TS and SGA or
cases of a family history predisposing to diabetes.
rhIGF-1 therapy
Severe primary IGF-I deficiency (height <3 SDS, serum
IGF-I <2·5th centile in EU and <3 SDS in USA, GH normal)
is a licensed indication for the use of rhIGF-I in Europe and the
USA.1 Given the rarity of this condition, patients should be
managed by an experienced paediatric endocrinologist. Patients
with severe primary IGF-I deficiency generally do not achieve
the same first-year HV with rhIGF-1 treatment as those with
severe GHD treated with GH because of the additional disrup-
tions of the IGF-I system.60 Subcutaneously administered exoge-
nous IGF-1 does not compensate for the lack of IGF-I
independent actions of GH at the growth plate and the pharma-
cokinetics of IGF-1 is affected by the deficiencies of the GH-
dependent ALS and IGFBP-3 carrier proteins. The response to
treatment with rhIGF-1 should be evaluated according to the
recommendations given for GH treatment above, although the
severity of the growth retardation, projected adult height and
lack of alternative therapy may be considered. On average,
responses to rhIGF-1 treatment are better when treatment is
started at a lower age and the response is dose dependent.11
However, the patient with extreme IGF-I deficiency does not
appear to be more sensitive to rhIGF-1 therapy11 and no rela-
tionship between change in HV and basal or stimulated serum
IGF-I has been seen.12
Adherence to GH therapy and its impact on response
Poor adherence may contribute to the variability in response to
GH therapy, although it may be of less concern during the first
year of therapy in prepubertal children.61 In the context of
adherence, serum IGF-I is the most commonly used biomarker
and its response to treatment is well characterized; although the
relative changes are smaller in disorders without GHD.2
Adherence to GH therapy involves daily and sometimes pain-
ful injections and physicians prescribing GH have to educate
patients and their families about the necessity, context and
objectives of the therapy. Individual psychological strain of treat-
ment is also likely to affect adherence, and ethnic and socio-
economic factors and the educational level of families are also
relevant.62,63 Adherence was reported to be better in children
who chose the injection device themselves, self-injected and were
trained by hospital staff.64
Impact of adherence on growth response
The impact of adherence on outcome to GH treatment has been
studied showing that non-adherence impaired the growth
response (Fig. 4).61,62,65 It remains unclear whether adherence
differs between the various indications for GH treatment.63 Most
studies of adherence with GH may not show an accurate picture
of the attitudes of the patients and their families.63 Informed
consent and shorter intervals between patient visits as practised
in GH treatment studies may improve motivation and reinforce
long-term adherence.
A number of GH injection devices are available and the
choice of product should be made on an individual basis tak-
ing into consideration therapeutic need and the likelihood of
adherence to treatment.64 Adherence may be improved by the
use of GH injection devices that include computerized pen
systems with skin sensors documenting the dose and fre-
quency of injections. However, the distinction between poor
growth as a result of non-compliance and non-responsiveness
may be difficult. A close link with an endocrine specialist
nurse will also facilitate good education to convince and
empower patients to use self-care strategies to achieve their
treatment goals.63
Management strategies for children with poor
response to GH therapy
As a general rule, the response to GH therapy should be
assessed following 12 months of therapy (Fig. 5).4,27,57 If a
patient demonstrates a poor response, further evaluation of the
diagnosis and indication for therapy is necessary. Several
options for further management can then be considered.
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Fig. 4 Height velocity standard deviation scores (HV SDS) over
6–8 months according to the level of compliance with GH treatment:
High (n = 30) missed  1 dose/week, Medium (n = 51) missed >1 and
<3 doses/week, and Low (n = 29) missed  3 doses per week. Data are
mean ± SEM. **P < 0·01, ***P < 0·001 vs High.62
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Repeated IGF-I measurements after 3 and 6 months of GH
therapy may be used for GH dose titration. If initial biochemi-
cal parameters suggested the existence of GH resistance, i.e.
low IGF-I with normal GH concentrations, IGF-I-based dose
titration should yield a GH dose able to overcome such GH
insensitivity. If this is not achieved, a disorder associated with
GH resistance should be considered, and rhIGF-1 therapy may
be indicated if the patient fulfils the criteria of severe primary
IGF-I deficiency. The mean first-year HV for ISS patients with
low IGF-I concentrations who were treated with rhIGF-1 for
1 year was similar to that reported for GH-treated prepubertal
children with ISS.12
Conclusions
The range of growth disorders treated with growth-promoting
therapy includes a large number of disorders which vary in their
phenotypic, biochemical and molecular characteristics. Conse-
quently, variability of inherent responsiveness and responses in
terms of short- and long-term change in height following treat-
ment with GH or rhIGF-1 is to be expected. Some components
of this variability can now be predicted and, therefore, prevented
by individualization of therapy. However, the reasons for others
remain obscure and it has to be accepted that not all growth
disorders are amenable to effective therapeutic management.
Recognition of poor or suboptimal response, however, will con-
tribute to the more effective management of short stature
together with an awareness of the most appropriate therapeutic
strategies and their implementation.
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